French Industry Welcomes Moves To Speed Up Access To Innovative Drugs
A French government/industry discussion forum has come up with concrete plans for accelerating access to innovative medicines by streamlining clinical trial approval and price negotiations.
You may also be interested in...
Leem says “Inconsistent and unpredictable” policies are hitting industry’s competitiveness and limiting patients’ access to new medicines.
Experimental gene and cell therapy products are to get a boost from the French regulator in the form of a new fast-track clinical trial approval process. This is the third accelerated pathway to be introduced as part of efforts to speed up patient access to new medicines.
The French government is proposing to extend the use of the temporary use authorization system for unapproved drugs and to increase the rate of generic prescribing. It has also set a low threshold for the increase in pharmaceutical sales that triggers the payback mechanism.